{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-076044","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2026-06-22T10:50:13+00:00","discovered_at":"2026-06-22T10:55:00.289590+00:00","generated_at":"2026-06-22T10:55:06.888353+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"uniQure reports AMT-260 Phase I/IIa data: 3/6 patients saw 79-100% seizure reduction; no SAEs","bullets":["Three of six patients in low-dose cohort achieved 79% to 100% decline in disabling seizures (months 4-6).","Remaining three patients had variable changes: -33% to +36% from baseline.","No serious adverse events related to AMT-260 or surgery; all AEs mild/moderate, headache most common (N=2).","Enrollment ongoing for second, higher-dose cohort (3x10¹² gc/mL), expected completion mid-2026; updated results H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-076044","json":"https://secwatch.observer/filing/0001104659-26-076044.json","markdown":"https://secwatch.observer/filing/0001104659-26-076044.md","text":"https://secwatch.observer/filing/0001104659-26-076044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926076044/0001104659-26-076044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926076044/qure-20260619x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T10:55:06.888353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}